From: Toll-like receptor 9 negatively related to clinical outcome of AML patients
Parameter | â„– | TLR9 (%) | p-value | ||
---|---|---|---|---|---|
Min.-Max. | Median | ||||
Sex: | Female | 16 | 0.10-2.40 | 1.35 | 0.699 |
Male | 24 | 0.12-2.40 | 1.30 | ||
Age group | < 65 years | 26 | 0.12-2.40 | 1.35 | 0.150 |
≥ 65 years | 14 | 0.10-2.00 | 1.07 | ||
FAB type | AML –M1 | 1 | 1.20 | 1.20 | 0.487 |
AML –M2 | 13 | 0.12-2.00 | 1.40 | ||
AML –M3 | 7 | 0.90-2.40 | 1.60 | ||
AML –M4 | 12 | 0.10-2.00 | 1.30 | ||
AML –M5 | 5 | 0.12-2.30 | 1.30 | ||
AML –M6 | 1 | 1.60 | 1.60 | ||
AML –M7 | 1 | 0.38 | 0.38 | ||
Outcome | Complete remission | 8 | 0.90-2.40 | 1.85 | 0.006* |
Partial remission | 12 | 0.12-2.30 | 1.50 | ||
Refractory | 4 | 0.12-1.60 | 0.70 | ||
Died | 14 | 0.10-1.60 | 0.925 | ||
Lost during follow up | 2 | 1.30-1.60 | 1.45 |